• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

免疫功能低下宿主严重急性呼吸综合征冠状病毒2聚合酶链反应长期阳性的抗病毒治疗结果：一项澳大利亚多中心回顾性病例系列研究

Outcomes of Antiviral Retreatment for Immunocompromised Hosts With Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Polymerase Chain Reaction Positivity: A Multicenter Australian Retrospective Case Series.

作者信息

Bond K A, Dendle C, Guy S, Slavin M A, Smibert O, Ibrahim N, Kinsella P M, Morrissey C O, Moso M A, Sasadeusz J J

机构信息

Department of Microbiology, Royal Melbourne Hospital, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.

Victorian Infectious Diseases Reference Laboratory, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.

出版信息

Open Forum Infect Dis. 2024 Aug 7;11(8):ofae449. doi: 10.1093/ofid/ofae449. eCollection 2024 Aug.

DOI:10.1093/ofid/ofae449
PMID:39189033
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11346352/
Abstract

Outcomes are presented for a multisite retrospective case series, describing a contemporary cohort of 22 immunocompromised patients with persistent coronavirus disease 2019 (COVID-19) polymerase chain reaction positivity who were retreated with antiviral therapy. For those with data available 14 and 30 days after commencement of antiviral therapy, 41% (9 of 22) and 68% (15 of 22), respectively, cleared COVID-19.

摘要

本文呈现了一个多中心回顾性病例系列的结果，描述了一组当代的22例免疫功能低下患者，这些患者持续性冠状病毒病2019（COVID-19）聚合酶链反应呈阳性，并接受了抗病毒治疗。对于那些在抗病毒治疗开始后14天和30天有可用数据的患者，分别有41%（22例中的9例）和68%（22例中的15例）清除了COVID-19。

相似文献

1
Outcomes of Antiviral Retreatment for Immunocompromised Hosts With Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Polymerase Chain Reaction Positivity: A Multicenter Australian Retrospective Case Series.免疫功能低下宿主严重急性呼吸综合征冠状病毒2聚合酶链反应长期阳性的抗病毒治疗结果：一项澳大利亚多中心回顾性病例系列研究
Open Forum Infect Dis. 2024 Aug 7;11(8):ofae449. doi: 10.1093/ofid/ofae449. eCollection 2024 Aug.
2
Antiviral therapies for the management of persistent coronavirus disease 2019 in immunocompromised hosts: A narrative review.免疫功能低下宿主中持续性 2019 冠状病毒病的抗病毒治疗：叙述性综述。
Transpl Infect Dis. 2024 Jun;26(3):e14301. doi: 10.1111/tid.14301. Epub 2024 May 29.
3
Emergence of SARS-CoV-2 Spike Mutations during Prolonged Infection in Immunocompromised Hosts.免疫功能低下宿主体内 SARS-CoV-2 刺突突变的长期感染中出现。
Microbiol Spectr. 2022 Jun 29;10(3):e0079122. doi: 10.1128/spectrum.00791-22. Epub 2022 May 11.
4
Epidemiological and Clinical Findings of Short-Term Recurrence of Severe Acute Respiratory Syndrome Coronavirus 2 Ribonucleic Acid Polymerase Chain Reaction Positivity in 1282 Discharged Coronavirus Disease 2019 Cases: A Multicenter, Retrospective, Observational Study.1282例新型冠状病毒肺炎出院患者严重急性呼吸综合征冠状病毒2核糖核酸聚合酶链反应阳性短期复发的流行病学和临床研究：一项多中心、回顾性、观察性研究
Open Forum Infect Dis. 2020 Sep 13;7(10):ofaa432. doi: 10.1093/ofid/ofaa432. eCollection 2020 Oct.
5
Prolonged viral positivity induced recurrent coronavirus disease 2019 (COVID-19) pneumonia in patients receiving anti-CD20 monoclonal antibody treatment: Case reports.接受抗 CD20 单克隆抗体治疗的患者中，病毒持续阳性导致复发性 2019 年冠状病毒病（COVID-19）肺炎：病例报告。
Medicine (Baltimore). 2021 Dec 30;100(52):e28470. doi: 10.1097/MD.0000000000028470.
6
Persistent and fatal severe acute respiratory syndrome coronavirus 2 infection in a patient with severe hypogammaglobulinemia: a case report.严重低丙种球蛋白血症患者持续性和致命性严重急性呼吸综合征冠状病毒 2 感染：一例报告。
J Med Case Rep. 2023 May 13;17(1):194. doi: 10.1186/s13256-023-03917-x.
7
Epidemiology, Clinical Features, and Disease Severity in Patients With Coronavirus Disease 2019 (COVID-19) in a Children's Hospital in New York City, New York.纽约市一家儿童医院的 2019 年冠状病毒病（COVID-19）患者的流行病学、临床特征和疾病严重程度。
JAMA Pediatr. 2020 Oct 1;174(10):e202430. doi: 10.1001/jamapediatrics.2020.2430. Epub 2020 Oct 5.
8
Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children.免疫功能低下儿童严重腺病毒疾病的静脉注射利巴韦林治疗
Pediatrics. 2002 Jul;110(1 Pt 1):e9. doi: 10.1542/peds.110.1.e9.
9
Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients.免疫功能低下患者持续性或复发性严重急性呼吸综合征冠状病毒 2 感染的 2 种抗病毒药物和单克隆抗体三联疗法。
Clin Infect Dis. 2023 Jul 26;77(2):280-286. doi: 10.1093/cid/ciad181.
10
Persistent Positivity of Reverse Transcriptase-Polymerase Chain Reaction Test among Patients with COVID-19 in Rural Teaching Hospital: A Descriptive Cross-sectional Study.农村教学医院 COVID-19 患者逆转录-聚合酶链反应检测的持续阳性：一项描述性横断面研究。
JNMA J Nepal Med Assoc. 2021 Nov 15;59(243):1136-1140. doi: 10.31729/jnma.7077.

本文引用的文献

1
COVID-19 Australia: Epidemiology Report 79: Reporting period ending 24 September 2023.《澳大利亚2019冠状病毒病：流行病学报告79》：报告期截至2023年9月24日。
Commun Dis Intell (2018). 2023 Nov 14;47. doi: 10.33321/cdi.2023.47.72.
2
Antiviral combination therapies for persistent COVID-19 in immunocompromised patients.免疫功能低下患者持续性 COVID-19 的抗病毒联合疗法。
Int J Infect Dis. 2023 Dec;137:55-59. doi: 10.1016/j.ijid.2023.09.021. Epub 2023 Sep 30.
3
Sequential or Combination Treatments as Rescue Therapies in Immunocompromised Patients with Persistent SARS-CoV-2 Infection in the Omicron Era: A Case Series.
在奥密克戎时代，序贯或联合治疗作为免疫功能低下的持续性严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染患者的挽救疗法：病例系列
Antibiotics (Basel). 2023 Sep 19;12(9):1460. doi: 10.3390/antibiotics12091460.
4
Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection.对体液免疫受损且SARS-CoV-2持续感染的患者采用瑞德西韦与奈玛特韦/利托那韦联合抗病毒治疗。
Hematol Oncol. 2023 Dec;41(5):904-911. doi: 10.1002/hon.3206. Epub 2023 Jul 15.
5
Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients.免疫功能低下患者持续性或复发性严重急性呼吸综合征冠状病毒 2 感染的 2 种抗病毒药物和单克隆抗体三联疗法。
Clin Infect Dis. 2023 Jul 26;77(2):280-286. doi: 10.1093/cid/ciad181.
6
Survey of treatment practices for immunocompromised patients with COVID-19 in Australasia.澳大利亚和新西兰免疫功能低下的 COVID-19 患者治疗实践调查。
Intern Med J. 2023 Apr;53(4):619-624. doi: 10.1111/imj.16064. Epub 2023 Apr 3.
7
Persistent SARS-CoV-2 infection in immunocompromised patients facilitates rapid viral evolution: Retrospective cohort study and literature review.免疫功能低下患者中持续的SARS-CoV-2感染促进病毒快速进化：回顾性队列研究与文献综述
Clin Infect Pract. 2022 Nov;16:100210. doi: 10.1016/j.clinpr.2022.100210. Epub 2022 Nov 16.
8
Novel treatment combining antiviral and neutralizing antibody-based therapies with monitoring of spike-specific antibody and viral load for immunocompromised patients with persistent COVID-19 infection.一种新型治疗方法，将抗病毒和基于中和抗体的疗法与对持续新冠病毒感染的免疫功能低下患者的刺突特异性抗体和病毒载量监测相结合。
Exp Hematol Oncol. 2022 Sep 9;11(1):53. doi: 10.1186/s40164-022-00307-9.
9
Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9).2021 年欧洲白血病感染会议（ECIL 9）关于血液系统恶性肿瘤或造血细胞移植患者 COVID-19 管理的建议。
Leukemia. 2022 Jun;36(6):1467-1480. doi: 10.1038/s41375-022-01578-1. Epub 2022 Apr 29.
10
Prolonged viral replication in patients with hematologic malignancies hospitalized with COVID-19.新冠病毒肺炎住院血液系统恶性肿瘤患者中病毒的持续复制
Haematologica. 2022 Jul 1;107(7):1731-1735. doi: 10.3324/haematol.2021.280407.